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Abstract 
As research previously demonstrated, suppression of AFP expression or its biological activities might inhibit the 
proliferation of AFP positive human hepatocellular carcinoma cells. In this study, we constructed an anti-AFP gene 
vector and transfected it to HepG2 cells. RT-PCR showed AFP gene expression in the transfected cells was reduced. 
MTT assay suggested the proliferation of the transfected cells was also inhibited comparing with the untransfected 
cells. This result provides a new insight into AFP as the target for preventing and treating hepatocellular carcinoma. 
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1. Introduction 
Hepatocellular carcinoma (HCC) is one of the most common malignant tumor worldwide.It is one of 
the leading causes of malignancy-related death in China. A number of strategies such as surgery, radiation, 
chemotherapy, and biological response modifiers have been applied for the treatment of HCC. However, 
there is still no satisfactory method to cuer the disease [1]. 
With the emerging revolutiin in cellular signaling transduction technology, more and more biological 
methods are used in treatment of cancer.Alpha-fetoprotein (AFP) is an oncoembryonal protein with 
multiple cell growth regulating, differentiating and immunosuppressive activities. It has been well 
characterized as a physiological carrier/transport protein for various ligands [2-5].As a diagnostic 
tumor-specific marker of hepatocellular carcinoma [6]  AFP can suppress the immune system and  help 
hepatocarcinomacells escape from immune surveillance.Besides, the relationship between AFP and HCC 
is far from clear. Recent investigations indicate that human AFP can enhance the proliferation of mouse 
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hepatoma H-22 and human hepatoma SMMC-7721, BEL-7404 or QGY-7703 cells in vitro[7,8].Similar 
growth stimulatory effect of low concentrations of AFP has been obtained in human hepatoma HepG2 
cells.These results have an important implication that suppression of AFP expression or its biological 
activities may be a new strategy for the treatment of AFP-associated tumors such as HCC. AFP shoule be 
a good target in gene therapy for HCC. 
Antisense oligodeoxynucleotides can prevent mRNA translation by forming RNA-DNA duplexes and 
Therefore, the inhibition effect of antisense oligodeoxynucleotides is in transcription level. Now antisense 
oligodeoxynucleotides technique has been commonly used to investigate their role in the treatment of 
human malignancies, both ex vivo and in vivo [10, 11].Moreover, in our previous research, we found that 
AFP-specific transfer fators could inhibit the growth of AFP positive HepG2 cells through downregulate 
AFP expression in post-transcription level [9].So in this report, we constructed a recombine 
antisense-AFP gene vector named pEGFP–anti-AFP and transfected the vector to HepG2 cells. Then cell 
viability was detected by MTT assay. The results suggest that the proliferation of cells transfected with 
antisense-AFP gene was evidently inhibited.  
2. Materials and methods  
2.1 Cell lines 
Hepatocarcinoma cell line HepG2 (AFP positive) were preserved in our laboratory. Cells were 
cultured in DMEM medium (Gibco) containing 10% fetal calf serum (Hyclone), 100 IU/ml penicillin and 
100 g/ml streptomycin sulfate (Amersco) at 37°C in saturated humidified air with 5% CO2. The cells 
were subcultured every two days. 
2.2 Reagents, bacterial strains and plasmids 
Emzymes and Reagents  DNA restriction endonuclease; Taq DNA polymerase; T4 DNA Ligase; 
DNA isolation and Purification kit (Dalian TakaRa Biotechnology, China) 
Bacterium and Vector  Escherichia coli DH5, pMD18-T Vector and pEGFP-N1 vector were 
conserved by laboratory. pCMV-SPORT6-AFP that bears the whole cDNA of AFP gene was purchased 
from Wuhan Sanying Biotechnology.  
Subcloning of antisense-AFP gene  PCR was used to amplify the antisense-AFP cDNA region of 
pCMV-SPORT6-AFP. In order to introduce Xho I and EcoR I sites into the sense and antisense chains 
respectively, a pair of PCR primers was designed using computer software (Primer Premier 5.0) as 
follows: Xho-AFP-5’: 5’ tc ctc gag gca acc atg aag tgg gtg gaa t 3’(sense), Eco-AFP-3’: 5’ gt gaa ttc g aac 
tcc caa agc agc acg agt 3’(antisense). PCR was performed in a total volume of 50 l consisting of 5 M 
each primer, 2.5mM each dNTP, 5 l 10×polymerase reaction buffer, 2.5U Pfu DNA polymerase and 2 l 
DNA template. The samples were heated to 94°C for 3 min followed by amplification for 35 cycles at 
94°C for 1min, 58°C for 1min, and 72°C for 3.5min. After the last cycle, a final extension step was at 
72°C for 5 min. Then 5 l of each product was analyzed by 1% agarose gel electrophoresis. PCR products 
were purified from the agarose gel using DNA purification kit . 
Construction of recombinant plasmid  After clean-up and A-tailing reaction with Pfu/A Amp Tailing 
Kit(Dalian TakaRa), PCR products of anti-AFP cDNA region and pMD18-T Vector were ligated with T4 
DNA Ligase, then the new plasmid, named pMD18-antisense-AFP, was transformed to DH5 cells to 
amplify. The pMD18-antisense-AFP and pEGFP-N1 were both doubly digested with Xho I and EcoR 
I.CIAP in this reaction system was used to dephosphorylate. We can obtain the full-length of 
antisense-AFP and pEGFP-N1 after the digested products were purified from the agarose gel using DNA 
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purification kit. Then the full-length antisense-AFP identified with Xho I and EcoR I cleavage was 
subcloned into expression vector pEGFP-N1. The recombinant plasmid was identified with restriction 
endonuclease Xh I and EcoR I cleavage, PCR amplification. Then it was confirmed by sequencing in 
TaKaRa. The obtained sequence data were compared with cDNA sequence from GenBank (Accession No. 
NM001168). Finally, the recombinant plasmid was transformed to DH5 cells to amplify. 
2.3 Transfection and identification of pEGFP-antisense-AFP to HepG2 cells  
HepG2 cell monolayers in a 96-well plate at a density of 1×104/well were transfected with 1–2 g per 
well of pEGFP-antisense-AFP by using 2-4 l LipofectamineTM 2000 reagent according to the 
manufacturer’s instructions (Invitrogen, Carlsbad, CA).  
RT-PCR was used to detect the expression of AFP gene in the transfected HepG2 cells. Briefly, total 
RNA of detected HepG2 cells was isolated using TRIzol reagent (Invitrogen). About 1 g of total RNA 
was used for first-strand cDNA synthesis with a kit according to the manufacturer’s instructions 
(Invitrogen).Then cDNAs were amplified with the following primer pairs: AFP, 
5’-AAAAGCCCACTCCAGCATC-3 and 5’-CAATCCAGCACATCTCCTC-3’; -actin was used as the 
control. The PCR products were separated on ethidium bromide stained agarose, and visualized with UV. 
Then we got the different expression of AFP gene in the detected HepG2 cells and validated successful 
transfection . 
Cells viability assay  After transfected cells were planted in 96-well cell culture plates (Costar, 
Corning, NY) for 24 h, Cell viability was determined by MTT assay [12].  
Statistical Analysis  The results were expressed as the mean ± SE accompanied by the number of 
experiments performed independently.  
3. Results 
3.1 Subcloning of antisense-AFP gene  
Figure 1 shows that antisense-AFP gene is successfully amplified. 
 
Fig.1 Subcloning of antisense-AFP gene 
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3.2 Construction of recombinant plasmid 
Fig.2 and Fig.3 indicate that pEGFP-antisense-AFP recombinant plasmid is successfully constructed. 
 
Fig.2 Digestion of pEGFP-N1 A and pMD18-antisense-AFP B with Xho I and EcoR I 
 
Fig.3 Digestion of pEGFP-antisense-AFP (A) with Xho I and EcoR I 
 Ze Wang and Hui Zhang /  Physics Procedia  33 ( 2012 )  31 – 37 35
 
3.3 Identification of pEGFP-antisense-AFP transfection in HepG2 cells 
Our study shows the best transfection efficiency is realized when 
pEGFP-antisense-AFP/LipofectamineTM 2000 is 1/2. RT-PCR shows the expression of AFP gene is 
decreased after transfection with pEGFP-antisense-AFP for 24h comparing with untransfected cells. 
 
Fig.4 RT-PCR shows AFP gene expression in the normal HepG2 cells (A) and the transfected HepG2 cells (B) 
3.4 Cells viability analysis 
After pEGFP-antisense-AFP vector transfected HepG2 cells for 24h, cell viability decreases to 
78.13%. 
 
 
Fig.5 MTT assay for normal HepG2 cells (A) and transfected HepG2 cells (B) 
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4. Discussion 
In recent years, the growth regulatory properties of AFP have aroused our interests. Studies involving 
ontogenetic and oncogenic growth in both cell cultures and animal models have been ongoing. 
Particularly, AFP can regulate the expression of some oncogene and cancer suppressor gene such as c-fos, 
c-jun, and N-ras [13]. Therefore, AFP has become the target gene in many investigations. Wang YS 
constructed AFP siRNAs expressing plasmid and studied the effect of AFP on hepatoma cells. They 
found treatment of SMMC-7721 cells with AFP siRNAs could inhibit the growth of SMMC-7721 [14]. 
Wang XW showed that AFP antisense phosphorothioate oligodeoxynucleotides effectively inhibited the 
growth of Bel7404 human hepatoma cells in vitro [15]. His another experiment indicated AFP antisense 
phosphorothioate oligodeoxynucleotides could inhibit tumour growth in Balb-c nude mice bearing 
SMMC-7721 tumors [16].  
We bought the pCMV-SPORT6 plasmid containing antisense-AFP gene and subcloned antisense-AFP 
gene. A pair of PCR primers was designed to introduce Xho and EcoR1 sites. PCR products were ligated 
with pMD18-T Vector. It was used to construct the recombine antisense-AFP gene vector named 
pEGFP-antisense-AFP through connecting with the plasmid of pEGFP-N1 after both doubly digested 
with Xho and EcoRI. Then we transfected the pEGFP-antisense-AFP to HepG2 cells by Lipofectamine 
2000. RT-PCR suggested that the expression of AFP gene was reduced in the transfected cells comparing 
with untransfected cells. Furthermore, we analyzed the growth activity of transfected and untransfected 
cells using MTT assay. We found that the growth of transfected cells had been inhibited. 
In our previous study, we use AFP as the antigen to prepare AFP-specific transfer factors (AFP–TF) 
and found for the first time that AFP–TF could inhibit the growth of Bel7402 and HepG2 AFP positive 
hepatocarcinoma cells, and induce their apoptosis [9]. However, we don’t find the apoptosis of 
transfected HepG2 cells in this research. So we consider that the downregulation of AFP expression 
induces growth inhibition of HepG2 cells, but not the apoptosis. 
In conclusion, the present results indicate that AFP antisense phosphorothioate oligodeoxynucleotides 
expressing plasmid exhibits significant antihepatoma activities in vitro. However, the mechanisms of its 
antihepatoma action are not through the induction of hepatoma cell apoptosis. 
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